Nyrada Inc. (ASX:NYR)
Australia · Delayed Price · Currency is AUD 0.5200
+0.0250 (5.05%)
Sep 25, 2026, 4:10 PM AEST
Nyrada Company Description
Nyrada Inc., a clinical-stage biotechnology company, focuses on the discovery and development of small-molecule therapies for neuroprotection and cardioprotection indications in Australasia.
Its lead candidate is Xolatryp, a small-molecule inhibitor targeting the transient receptor potential canonical ion channel subtypes 3, 6, and 7, which is in a Phase IIa clinical trial to treat myocardial ischemia, arrhythmia, stroke, and traumatic brain injury, as well as in a preclinical research stage for oncology indications.
Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Contact Details
Address: Salesforce Tower, Sydney Place Sydney, NSW 2000 Australia | |
| Phone | 61 2 9498 3390 |
| Website | nyrada.com |
Stock Details
| Ticker Symbol | NYR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000070195 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Bonnar | Chief Executive Officer, MD and Director |
| Cameron Peter Jones C.A. | Chief Financial Officer |
| Benjamin Evison Ph.D. | Chief Scientific Officer |
| Dimitri Burshtein | Investor Relations Manager |
| Mark Waring B.Sc., P.M.P. | Senior Vice President of US Operations |
| David James Franks BEc, C.A., F Fin, J.P. | Company Secretary |
| Jasneet Parmar | Director of Research and Development |
| Dr. Alex Suchowerska | Director of Clinical Development and Regulatory Affairs |